DexCom, Inc. (DXCM)
| Market Cap | 38.69B |
| Revenue (ttm) | 1.93B |
| Net Income (ttm) | 493.60M |
| Shares Out | 94.40M |
| EPS (ttm) | 5.06 |
| PE Ratio | 79.06 |
| Forward PE | 169.49 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $400.04 |
| Previous Close | $399.49 |
| Change ($) | 0.55 |
| Change (%) | 0.14% |
| Day's Open | 400.57 |
| Day's Range | 393.64 - 401.65 |
| Day's Volume | 550,050 |
| 52-Week Range | 305.63 - 456.23 |
EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today it has ended its distributi...
Will future Tyvaso revenue growth push United Therapeutics to new heights?
SAN DIEGO--(BUSINESS WIRE)--Dexcom Schedules First Quarter 2021 Earnings Release and Conference Call for April 29, 2021 at 4:30 p.m. Eastern Time.
Financial media can often divert your attention away from the best investments.
SAN DIEGO--(BUSINESS WIRE)---- $DXCM--Dexcom Promotes Jereme Sylvain to Chief Financial Officer
Tandem Diabetes (TNDM) is expects t:sport to be a major growth catalyst for 2022.
Toxic stocks are vulnerable to external shocks and are burdened with huge debts. It's important to ensure that you safeguard your portfolio from such stocks.
When the market is expensive and overbought like the current one is, it is very important to stay with companies that not only have solid earnings potential but also have upcoming catalysts that can hel...
Toxic stocks usually carry huge debt load and are vulnerable to external shocks. They should be timely discarded from one's portfolio to avoid wealth erosion.
DexCom Inc. (NASDAQ:DXCM) said it expects 2021 revenue to increase between 15% and 20% to more than $2.2 billion as it extends its diabetes care business into two new areas of the disease, prediabetes a...
If the market plunges, picking up these fast-paced companies at a discount would be a wise move.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Upcoming Virtual Conference Presentations
DexCom CEO says Super Bowl ad sparked high interest in its glucose tracker
DexCom CEO Kevin Sayer said the company had 5 times more media impressions in one day than it had all last year after airing Super Bowl spot featuring Nick Jonas, helping to get the message out about it...
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.
DexCom (DXCM) delivered earnings and revenue surprises of 0.00% and 1.88%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO--(BUSINESS WIRE)--Dexcom Launches Inaugural Venture Capital Fund
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Fourth Quarter 2020 Financial Results
DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.
The stock price of DexCom, best known for its continuous glucose monitoring systems, has risen by 10% over the last five trading days. Earlier in January, the company reported strong preliminary numbers...
Hint: Much of a company's success has to do with the experiences and diversity of its leadership.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Schedules Fourth Quarter and Full Year 2020 Earnings Release and Conference Call for February 11, 2021 at 4:30 p.m. Eastern Time.
The stock market's benchmark index is packed with big-time value.
DexCom (DXCM) posts solid fourth-quarter and full-year 2020 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.
Teladoc (TDOC) and Dexcom jointly provide solutions for patients with Type 2 diabetes, a common lifestyle-induced malady.
These two providers of diabetes-related products and services have yet to scratch the surface of their potential.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2020 and Provides Initial 2021 Outlook
DexCom (DXCM) closed the most recent trading day at $388.09, moving +0.24% from the previous trading session.
SAN DIEGO--(BUSINESS WIRE)--Dexcom to Present at 39th Annual J.P. Morgan Healthcare Conference
These stocks can handle whatever the new year has in store.
The highflying Nasdaq 100 is hiding some serious value in plain sight.
In the latest trading session, DexCom (DXCM) closed at $355.02, marking a -0.27% move from the previous day.
DexCom is an attractive company riding a long-term secular trend in the growth of chronic care management. Stock has performed well this year and is trading at the high range of historical averages.
DexCom (DXCM) closed at $358.57 in the latest trading session, marking a +0.18% move from the prior day.
This healthcare technology company is disrupting the diabetes market with innovative technologies that patients love.
DexCom CEO: We're more bullish about the business than we've ever been
DexCom CEO Kevin Sayer reaffirms his long-term outlook for the diabetes management company, forecasting growth as high as 20% through 2025.
Investors have a few questions as the company faces increasing competition.
These companies have growth opportunities that will last long after the COVID vaccine gets life back to normal.
These stocks could make you a fortune over the next decade.
Medical device which has for long taken tiny steps toward IoMT is now going all out to make the most of the advancements in this space amid the pandemic.
Probably not, but it'll still beat the market.
Biotech stocks simply can't match these reliable returns.
These two companies are battling for market share of continuous glucose monitoring devices for diabetes, with each coming out with new models soon.
G7 could change the valuation dramatically. It is a risky play, especially in the short term.
Instead of investing in the company that would have made you a millionaire years ago, seek out the ones that have the potential from here.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Upcoming Virtual Conference Presentations
These stocks have beaten the odds in 2020 and can weather future storms.
With the disruption that the coronavirus caused us, the dependency on tech-based solutions makes these IoT stocks very relevant. The post 7 IoT Stocks That Are Banking on a Connected Future appeared fir...
An analyst downgrade and marketwide turbulence weighed on the medical device maker's shares last month.
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LL... [Read more...]
| Industry Diagnostics & Research | IPO Date Apr 14, 2005 |
| CEO Kevin Sayer | Employees 5,500 |
| Stock Exchange NASDAQ | Ticker Symbol DXCM |
Financial Performance
In 2020, DexCom's revenue was $1.93 billion, an increase of 30.54% compared to the previous year's $1.48 billion. Earnings were $493.60 million, an increase of 388.23%.
Analyst Forecasts
According to 21 analysts, the average rating for DexCom stock is "Buy." The 12-month stock price forecast is 466.00, which is an increase of 16.49% from the latest price.